Display options
Share it on

Harm Reduct J. 2009 May 29;6:8. doi: 10.1186/1477-7517-6-8.

Can abuse deterrent formulations make a difference? Expectation and speculation.

Harm reduction journal

Simon H Budman, Jill M Grimes Serrano, Stephen F Butler

Affiliations

  1. Inflexxion, Inc., Newton, Massachusetts, USA. [email protected]

PMID: 19480676 PMCID: PMC2694768 DOI: 10.1186/1477-7517-6-8

Abstract

It is critical that issues surrounding the abuse and misuse of prescription opioids be balanced with the need for these medications for the treatment of pain. One way to decrease the abuse of prescription opioid medications is to develop abuse deterrent formulations (or ADFs) that in some way prevent drug abusers from extracting out the active ingredient in order to employ alternate routes of administration, such as injection, snorting, and smoking. Several factors including the pharmacokinetic profile of the drug, the features of the drug formulation that make it attractive or unattractive for abuse, the type of drug abuser, the progression of one's addiction pathway, and one's social environment may all play a role in the abuse of prescription opioids and what methods are used to abuse these drugs. This paper will examine these factors in order to understand how they affect the abuse of prescription opioids and routes of administration, and how the development of ADFs may alter these patterns.

References

  1. Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1142-54 - PubMed
  2. Br J Addict. 1991 Dec;86(12):1601-6 - PubMed
  3. Int J Drug Policy. 2007 Oct;18(5):352-8 - PubMed
  4. Psychopharmacology (Berl). 1993;112(2-3):324-30 - PubMed
  5. J Exp Anal Behav. 1973 Jul;20(1):119-29 - PubMed
  6. Subst Use Misuse. 2008;43(3-4):413-28 - PubMed
  7. J Drug Issues. 2007;37(3):717-736 - PubMed
  8. Drug Alcohol Depend. 2007 Jul 10;89(2-3):244-50 - PubMed
  9. Psychopharmacology (Berl). 1992;107(2-3):352-8 - PubMed
  10. J Nerv Ment Dis. 2006 Aug;194(8):577-83 - PubMed
  11. J R Soc Med. 1992 Aug;85(8):469-72 - PubMed
  12. Addiction. 2003 Jan;98(1):83-91 - PubMed
  13. J Pharmacol Exp Ther. 2001 Dec;299(3):1056-65 - PubMed
  14. Subst Use Misuse. 2006;41(2):245-54 - PubMed
  15. Drug Alcohol Depend. 2001 Nov 1;64(3):285-98 - PubMed
  16. Addiction. 1995 May;90(5):607-14 - PubMed
  17. Clin J Pain. 2007 Feb;23(2):103-18 - PubMed
  18. Drug Alcohol Depend. 2003 Jun 5;70(3):275-86 - PubMed
  19. JAMA. 2008 Dec 10;300(22):2613-20 - PubMed
  20. Harm Reduct J. 2006 Feb 02;3:5 - PubMed
  21. Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S15-22 - PubMed
  22. Int J Drug Policy. 2009 Jul;20(4):317-23 - PubMed
  23. Curr Rheumatol Rep. 2008 Jan;10(1):11-8 - PubMed
  24. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 Feb;15(1):53-9 - PubMed
  25. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):493-503 - PubMed
  26. Drug Alcohol Depend. 2006 Sep 15;84(2):154-9 - PubMed
  27. J Manag Care Pharm. 2005 Jul-Aug;11(6):469-79 - PubMed
  28. Drug Alcohol Depend. 2007 Jul 10;89(2-3):234-43 - PubMed
  29. NIDA Res Monogr. 1992;120:13-25 - PubMed
  30. Am J Addict. 1999 Spring;8(2):148-60 - PubMed
  31. Drug Alcohol Depend. 2008 Oct 1;97(3):237-46 - PubMed
  32. Drug Alcohol Depend. 2007 May 11;88(2-3):182-7 - PubMed
  33. J Anal Toxicol. 1994 Oct;18(6):317-30 - PubMed
  34. Am J Drug Alcohol Abuse. 2008;34(4):499-509 - PubMed
  35. Drug Alcohol Depend. 2008 Aug 1;96(3):281-5 - PubMed
  36. Pain Physician. 2006 Jan;9(1):1-39 - PubMed
  37. Anesth Analg. 2007 Jul;105(1):205-21 - PubMed
  38. Drug Alcohol Depend. 2006 Jun 28;83(2):104-10 - PubMed

Publication Types